Pharmacological, hematological, and physiological effects of a new thromboxane synthetase inhibitor (CGS-13080) during cardiopulmonary bypass in dogs

William M. DeCampli, David Goodwin, Jon C. Kosek, Cynthia E. Handen, R. Scott Mitchell, D. Craig Miller, Abelardo DeAnda

Research output: Contribution to journalArticle

Abstract

The hematological and pharmacological effects of a new thromboxane synthetase inhibitor, CGS-13080 (imidazo[1,5-α]pyridine-5-hexanoic acid), were investigated during cardiopulmonary bypass in a blinded, randomized manner in dogs. Compared with placebo, CGS-13080 suppressed thrombin-stimulated platelet thramboxane B2 production by 90% during cardfopulmonary bypass (p 1α levels significantly increased over time (p 2 per platelet following in vitro thrombin stimulation (r = .5, p .10) in the CGS-13080-treated group. No adverse hemodynamic or other effects attributable to CGS-13080 occurred during or immediately following cardiopulmonary bypass. These results suggest that CGS-13080 is an effective inhibitor of thromboxane B2 production during cardiopulmonary bypass in dogs and has no adverse physiological effects.

Original languageEnglish (US)
Pages (from-to)778-780
Number of pages3
JournalThe Annals of Thoracic Surgery
Volume57
Issue number3
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Thromboxane-A Synthase
Cardiopulmonary Bypass
Pharmacology
Dogs
Thrombin
Blood Platelets
Thromboxane B2
Hemodynamics
Placebos
pirmagrel

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Pharmacological, hematological, and physiological effects of a new thromboxane synthetase inhibitor (CGS-13080) during cardiopulmonary bypass in dogs. / DeCampli, William M.; Goodwin, David; Kosek, Jon C.; Handen, Cynthia E.; Mitchell, R. Scott; Miller, D. Craig; DeAnda, Abelardo.

In: The Annals of Thoracic Surgery, Vol. 57, No. 3, 1994, p. 778-780.

Research output: Contribution to journalArticle

DeCampli, William M. ; Goodwin, David ; Kosek, Jon C. ; Handen, Cynthia E. ; Mitchell, R. Scott ; Miller, D. Craig ; DeAnda, Abelardo. / Pharmacological, hematological, and physiological effects of a new thromboxane synthetase inhibitor (CGS-13080) during cardiopulmonary bypass in dogs. In: The Annals of Thoracic Surgery. 1994 ; Vol. 57, No. 3. pp. 778-780.
@article{51655bebaa1f41ce81c09a7023012715,
title = "Pharmacological, hematological, and physiological effects of a new thromboxane synthetase inhibitor (CGS-13080) during cardiopulmonary bypass in dogs",
abstract = "The hematological and pharmacological effects of a new thromboxane synthetase inhibitor, CGS-13080 (imidazo[1,5-α]pyridine-5-hexanoic acid), were investigated during cardiopulmonary bypass in a blinded, randomized manner in dogs. Compared with placebo, CGS-13080 suppressed thrombin-stimulated platelet thramboxane B2 production by 90{\%} during cardfopulmonary bypass (p 1α levels significantly increased over time (p 2 per platelet following in vitro thrombin stimulation (r = .5, p .10) in the CGS-13080-treated group. No adverse hemodynamic or other effects attributable to CGS-13080 occurred during or immediately following cardiopulmonary bypass. These results suggest that CGS-13080 is an effective inhibitor of thromboxane B2 production during cardiopulmonary bypass in dogs and has no adverse physiological effects.",
author = "DeCampli, {William M.} and David Goodwin and Kosek, {Jon C.} and Handen, {Cynthia E.} and Mitchell, {R. Scott} and Miller, {D. Craig} and Abelardo DeAnda",
year = "1994",
doi = "10.1016/0003-4975(94)90597-5",
language = "English (US)",
volume = "57",
pages = "778--780",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Pharmacological, hematological, and physiological effects of a new thromboxane synthetase inhibitor (CGS-13080) during cardiopulmonary bypass in dogs

AU - DeCampli, William M.

AU - Goodwin, David

AU - Kosek, Jon C.

AU - Handen, Cynthia E.

AU - Mitchell, R. Scott

AU - Miller, D. Craig

AU - DeAnda, Abelardo

PY - 1994

Y1 - 1994

N2 - The hematological and pharmacological effects of a new thromboxane synthetase inhibitor, CGS-13080 (imidazo[1,5-α]pyridine-5-hexanoic acid), were investigated during cardiopulmonary bypass in a blinded, randomized manner in dogs. Compared with placebo, CGS-13080 suppressed thrombin-stimulated platelet thramboxane B2 production by 90% during cardfopulmonary bypass (p 1α levels significantly increased over time (p 2 per platelet following in vitro thrombin stimulation (r = .5, p .10) in the CGS-13080-treated group. No adverse hemodynamic or other effects attributable to CGS-13080 occurred during or immediately following cardiopulmonary bypass. These results suggest that CGS-13080 is an effective inhibitor of thromboxane B2 production during cardiopulmonary bypass in dogs and has no adverse physiological effects.

AB - The hematological and pharmacological effects of a new thromboxane synthetase inhibitor, CGS-13080 (imidazo[1,5-α]pyridine-5-hexanoic acid), were investigated during cardiopulmonary bypass in a blinded, randomized manner in dogs. Compared with placebo, CGS-13080 suppressed thrombin-stimulated platelet thramboxane B2 production by 90% during cardfopulmonary bypass (p 1α levels significantly increased over time (p 2 per platelet following in vitro thrombin stimulation (r = .5, p .10) in the CGS-13080-treated group. No adverse hemodynamic or other effects attributable to CGS-13080 occurred during or immediately following cardiopulmonary bypass. These results suggest that CGS-13080 is an effective inhibitor of thromboxane B2 production during cardiopulmonary bypass in dogs and has no adverse physiological effects.

UR - http://www.scopus.com/inward/record.url?scp=0028315918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028315918&partnerID=8YFLogxK

U2 - 10.1016/0003-4975(94)90597-5

DO - 10.1016/0003-4975(94)90597-5

M3 - Article

C2 - 7511885

AN - SCOPUS:0028315918

VL - 57

SP - 778

EP - 780

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 3

ER -